Eli Lilly Halted Sales Of 340B Drugs To Contract Pharmacies, Except For Insulin

As of September 1, 2020, Eli Lilly is no longer offering drugs discounted under the 340B program to contract pharmacies, except for insulin. The company believes that the discounts intended for consumers through the 340B program are not reaching them at the pharmacy counter. In an announcement on September 2, 2020, the company said that under the current 340B program, Lilly sells many of its insulins for a penny per milliliter (mL), but consumers pay much higher prices due to supply chain markups.

Under this new approach, Lilly will only provide 340B “penny priced” insulin to 340B covered entities for . . .